Targovax 2021
Targovax er et selskap i vinden. Hva ser vi for oss fremover?
Redigert 21.01.2021 kl 09:20
Du må logge inn for å svare
flusher99
25.03.2021 kl 13:44
3322
Styrekompensasjon i Targovax
Styret i Targovax består av 8 personer, 1 leder og 7 medlemmer. Styret kompenseres med totalt kr. 2 615 000kr(515 000+300 000*7. Medlemmene i styret valgte å ta ut totalt kr 1 071 4178 i RSU'er, med kurs på kr. 8,80 Dette tilsvarer totalt 41% av kompensasjonen.
https://newsweb.oslobors.no/message/528017
Styret i Targovax består av 8 personer, 1 leder og 7 medlemmer. Styret kompenseres med totalt kr. 2 615 000kr(515 000+300 000*7. Medlemmene i styret valgte å ta ut totalt kr 1 071 4178 i RSU'er, med kurs på kr. 8,80 Dette tilsvarer totalt 41% av kompensasjonen.
https://newsweb.oslobors.no/message/528017
morgendagen
30.03.2021 kl 10:41
3079
Jaja, nå var denne snart tilbake på 7 tallet igjen.
ingen som tørr eller kjøper «Titanic», denne går ned til neste melding så er vi jo tilbake på 9 tallet igjen.
I mellom tiden så kan vel styret godkjenne emisjonen og utdeling av nye bonuser/godtgjørelser.
ingen som tørr eller kjøper «Titanic», denne går ned til neste melding så er vi jo tilbake på 9 tallet igjen.
I mellom tiden så kan vel styret godkjenne emisjonen og utdeling av nye bonuser/godtgjørelser.
Sukiyaki
30.03.2021 kl 11:23
3022
Styret er jævlig gode på opsjoner og bonuser, men helt ræva på emisjoner.
dalglish
30.03.2021 kl 12:52
2946
Til slutt er det hverken opsjoner eller emisjoner som betyr noe i det store bildet, men om Øystein Soug klarer å gjenskape magien fra Algeta. Der var det også en og annen opsjon og emisjon, men vi klagde ikke når budet fra Bayer kom :-)
Sukiyaki
30.03.2021 kl 13:11
2914
Det var det da. Oppkjøp har en kunne lest på forumet i årevis, så det er nok det mange drømmer om og håper på. Skjer det ???
quattro
30.03.2021 kl 13:43
2871
Strategien til selskapet TRVX er å ta sine produkt kandidater til og med fase2 - deretter skal det skapes aksjonær verdier - det er strategien til administrasjonen og det er strategien til styret - så kan du selv vurdere oppkjøps mulighetene for selskapet, resultater er avgjørende og de er gode, selv om markedet anser muligheten for meget små p.t (se på mcap) i mens beveger i oss nærmere et delmål eller et strategisk mål, eller en total fiasko (noe som ikke underbygges p.t av oppnådde data)
😎
😎
domboshawa
30.03.2021 kl 14:42
2830
Resultatene er veldig gode, men jeg tror at pasientgruppene er for små til at BP kaster seg over dem. ØS kommentar «vi vil ikke gi bort selskapet heller» tyder på kontakt og dialog med en eller flere av de store som ikke har innfridd i forhold til selskapets forventninger.
quattro
30.03.2021 kl 15:54
2775
Merck samarbeidet med Idera som hadde høy ORR score i sine innledende forsøk i fase I og II, men i fase III gikk de på trynet som det heter, og dette ble 'forklart' med mulig ''cherry picking'' av pasient populasjonen - tror ikke Merck lar være å se på pasient grunnlaget til TRVX som alle var i kategori III og IV som er en gruppe dårlige pasienter, men med Idera samarbeidet friskt i minne kan det gjøre Merck mer tilbakeholden ...... så tror heller ikke på oppkjøp nå, men trolig etter fullført fase II dersom resultatene kan gjennskapes, dog kan Merck samarbeide med TRVX med CPI'ene og forhåpningsvis noe snabba cash ......
tegr
07.04.2021 kl 09:17
2444
Næringsministere mener at Norge er i ferd med å bygge opp en betydelig helsenæring som når ut til globale markeder. De siste årene har vi sett flere kommersielle suksesshistorier innenfor helsenæringen. Dette er lovende for både pasienter og verdiskaping i landet.
https://www.dagensmedisin.no/artikler/2021/03/29/verdiskaping-i-helse/
https://www.dagensmedisin.no/artikler/2021/03/29/verdiskaping-i-helse/
SomSa
07.04.2021 kl 14:34
2252
Lenge har Magnus sagt at det akademiske miljø rund om kring har stor vist interesse for mesothelioma studien og ville være videre med........ Vi må håpe på at Soug har ikke falt i koma og melder om at en del av/hele studien sponses av dem. Det beste har vært liknende avtale som de fikk for eggstokk og tykktramkreft i USA. Det vil si at de dekker studiekostnader og hvis det blir suksess skal TRVX betale tilbake disse kostnadene. Og med dette vil TRVX sitte med alle rettigheter og salgsinntekter.
Redigert 07.04.2021 kl 14:53
Du må logge inn for å svare
Sukiyaki
07.04.2021 kl 19:07
2110
Hvilken avtaler og hva som skjer innad i TRVX, hvem vet. Hele gjengen har nok dessverre falt i koma for lenge siden.
SomSa
08.04.2021 kl 11:57
1900
Dette var resultatet for Xofigo fra Algeta (under 3 måneder bedre), hva er for Oncos-102 og mesothelioma :
Xofigo significantly improved OS in the overall study population at the pre-
specified interim analysis (HR=0.695, (95% CI 0.552-0.875), p=0.00185); median
OS was 14.0 months with Xofigo plus best standard of care (95% CI: 12.1-15.8)
vs. 11.2 months with placebo plus best standard of care (95% CI: 9.0-13.2).
These findings were supported by the exploratory analysis performed before
patient crossover with an additional 214 events in which Xofigo showed
improvement in OS (HR=0.695, (95% CI 0.581-0.832); median OS was 14.9 months in
the Xofigo arm (95% CI: 13.9-16.1) vs 11.3 months in the placebo arm (95% CI:
10.4-12.8).
https://www.globenewswire.com/news-release/2013/11/15/590197/10058215/en/Algeta-ASA-Xofigo-R-radium-Ra-223-dichloride-injection-granted-Marketing-Authorization-in-the-European-Union.html
Redigert 08.04.2021 kl 12:00
Du må logge inn for å svare
flusher99
11.06.2021 kl 08:24
1411
Solid dekning etter at gårsdagens resultater ble offentliggjort:
Targovax's ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival
NEWS PROVIDED BY
Targovax
10 Jun, 2021, 12:44 BST
SHARE THIS ARTICLE
- Median overall survival (mOS) for first-line treatment with ONCOS-102 plus chemotherapy will be between 21.9 and 25.0 months, compared with mOS of 13.5 months in the chemotherapy-only control group
- Broad and powerful immune activation pattern observed in patients treated with ONCOS-102, clearly associated with both tumor responses and survival outcomes
OSLO, Norway, June 10, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces mOS between 21.9 and 25.0 months from the randomized phase 1/2 trial of ONCOS-102 in combination with Standard of Care (SoC) chemotherapy in patients with malignant pleural mesothelioma (MPM).
For information in Norwegian,press this link.
The study is an open-label, exploratory phase 1/2 trial adding ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin) in first- and second- (or later) line MPM to assess safety, immune activation and clinical efficacy compared with SoC alone. A total of 31 patients were enrolled in the trial, with 20 patients in the treatment group receiving ONCOS-102 plus SoC chemotherapy, and 11 patients in the control group receiving SoC only. The trial has now completed the 24-month follow-up.
At the 24-month follow-up, it was determined that the final mOS will be in the range of 21.9 to 25.0 months for first-line ONCOS-102-treated patients in the randomized group (n=8). This is a clear improvement over the mOS of 13.5 months observed in the first-line SoC-only control group (n=6). Previous MPM clinical trials have reported mOS in the range of 12–16 months for patients receiving the same SoC chemotherapy treatment[1].
Immune activation was assessed in tumor biopsies pre- and post-ONCOS-102 treatment (Day 36). The tumor tissue analyses revealed broad and powerful ONCOS-102-induced remodeling of the tumor microenvironment with increased T-cell infiltration and a shift towards pro-inflammatory immune cells, far beyond what was observed for the SoC-only control group. Notably, this activity was associated with both tumor responses and survival outcomes, indicating that the immune activation generated by ONCOS-102 is driving the clinical benefit for patients.
Dr. Luis Paz-Ares, Chair of the Medical Oncology Department at the Hospital Doce de Octubre, Madrid and Principal Investigator of the trial, said: "Mesothelioma remains a challenging disease with a generally poor prognosis, and there is a large unmet medical need for new, innovative treatments such as ONCOS-102. Although the number of patients in this trial is small, the overall survial is very encouraging, particularly since the outcomes can be linked to ONCOS-102-induced immuno-modulation. These early results clearly support further clinical development, and we look forward to participating in future trials with ONCOS-102 in mesothelioma."
Recently, the double checkpoint inhibitor (CPI) combination of Opdivo and Yervoy (nivolumab and ipilimumab) was approved by the U.S. Food and Drug Administration (October 2020) and the European Medicines Agency (April 2021) for the first-line treatment of MPM, based on a phase 3 trial showing mOS of 18.1 months compared with 14.1 months in the SoC control group (pemetrexed/cisplatin). The Opdivo/Yervoy combination is seeing rapid uptake among clinicians in both the USA and Europe and is becoming the new preferred first-line Standard of Care. Given the class-leading activity ONCOS-102 has demonstrated in CPI-refractory melanoma (see link here), Targovax believes there is a strong scientific rationale for testing ONCOS-102 in the CPI-refractory setting also in MPM. This opportunity is now being discussed with key opinion leaders.
Øystein Soug, CEO of Targovax, commented: "We are very pleased to see ONCOS-102 generating robust immune activation in a tumor type with low immunogenicity and delivering meaningful survival benefit for patients with high medical need. With the recent approval of the Opdivo/Yervoy combination, the power of immunotherapy is now making its way into mesothelioma and is already improving patient outcomes. ONCOS-102 is ideally positioned for combination with checkpoint inhibitors and, as demonstrated in our melanoma trial, to reactivate checkpoint resistant tumors. Therefore, we are now evaluating the potential opportunity in the emerging checkpoint resistant mesothelioma population, thereby expanding on the demonstrated ability of ONCOS-102 to bring benefit to the majority of patients who still progress after checkpoint inhibitor treatment."
[1] 1 Vogelzang 2003, Ceresoli 2006, Zalcman 2015, Tsao 2019, Scagliotti 2019, Baas 2020 SITC 2020 poster
For further information, please contact:
Øystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/targovax/r/targovax-s-oncos-102-mesothelioma-24-month-data-shows-class-leading-median-overall-survival,c3364714
https://www.prnewswire.co.uk/news-releases/targovax-s-oncos-102-mesothelioma-24-month-data-shows-class-leading-median-overall-survival-803277007.html
Targovax's ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival
NEWS PROVIDED BY
Targovax
10 Jun, 2021, 12:44 BST
SHARE THIS ARTICLE
- Median overall survival (mOS) for first-line treatment with ONCOS-102 plus chemotherapy will be between 21.9 and 25.0 months, compared with mOS of 13.5 months in the chemotherapy-only control group
- Broad and powerful immune activation pattern observed in patients treated with ONCOS-102, clearly associated with both tumor responses and survival outcomes
OSLO, Norway, June 10, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces mOS between 21.9 and 25.0 months from the randomized phase 1/2 trial of ONCOS-102 in combination with Standard of Care (SoC) chemotherapy in patients with malignant pleural mesothelioma (MPM).
For information in Norwegian,press this link.
The study is an open-label, exploratory phase 1/2 trial adding ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin) in first- and second- (or later) line MPM to assess safety, immune activation and clinical efficacy compared with SoC alone. A total of 31 patients were enrolled in the trial, with 20 patients in the treatment group receiving ONCOS-102 plus SoC chemotherapy, and 11 patients in the control group receiving SoC only. The trial has now completed the 24-month follow-up.
At the 24-month follow-up, it was determined that the final mOS will be in the range of 21.9 to 25.0 months for first-line ONCOS-102-treated patients in the randomized group (n=8). This is a clear improvement over the mOS of 13.5 months observed in the first-line SoC-only control group (n=6). Previous MPM clinical trials have reported mOS in the range of 12–16 months for patients receiving the same SoC chemotherapy treatment[1].
Immune activation was assessed in tumor biopsies pre- and post-ONCOS-102 treatment (Day 36). The tumor tissue analyses revealed broad and powerful ONCOS-102-induced remodeling of the tumor microenvironment with increased T-cell infiltration and a shift towards pro-inflammatory immune cells, far beyond what was observed for the SoC-only control group. Notably, this activity was associated with both tumor responses and survival outcomes, indicating that the immune activation generated by ONCOS-102 is driving the clinical benefit for patients.
Dr. Luis Paz-Ares, Chair of the Medical Oncology Department at the Hospital Doce de Octubre, Madrid and Principal Investigator of the trial, said: "Mesothelioma remains a challenging disease with a generally poor prognosis, and there is a large unmet medical need for new, innovative treatments such as ONCOS-102. Although the number of patients in this trial is small, the overall survial is very encouraging, particularly since the outcomes can be linked to ONCOS-102-induced immuno-modulation. These early results clearly support further clinical development, and we look forward to participating in future trials with ONCOS-102 in mesothelioma."
Recently, the double checkpoint inhibitor (CPI) combination of Opdivo and Yervoy (nivolumab and ipilimumab) was approved by the U.S. Food and Drug Administration (October 2020) and the European Medicines Agency (April 2021) for the first-line treatment of MPM, based on a phase 3 trial showing mOS of 18.1 months compared with 14.1 months in the SoC control group (pemetrexed/cisplatin). The Opdivo/Yervoy combination is seeing rapid uptake among clinicians in both the USA and Europe and is becoming the new preferred first-line Standard of Care. Given the class-leading activity ONCOS-102 has demonstrated in CPI-refractory melanoma (see link here), Targovax believes there is a strong scientific rationale for testing ONCOS-102 in the CPI-refractory setting also in MPM. This opportunity is now being discussed with key opinion leaders.
Øystein Soug, CEO of Targovax, commented: "We are very pleased to see ONCOS-102 generating robust immune activation in a tumor type with low immunogenicity and delivering meaningful survival benefit for patients with high medical need. With the recent approval of the Opdivo/Yervoy combination, the power of immunotherapy is now making its way into mesothelioma and is already improving patient outcomes. ONCOS-102 is ideally positioned for combination with checkpoint inhibitors and, as demonstrated in our melanoma trial, to reactivate checkpoint resistant tumors. Therefore, we are now evaluating the potential opportunity in the emerging checkpoint resistant mesothelioma population, thereby expanding on the demonstrated ability of ONCOS-102 to bring benefit to the majority of patients who still progress after checkpoint inhibitor treatment."
[1] 1 Vogelzang 2003, Ceresoli 2006, Zalcman 2015, Tsao 2019, Scagliotti 2019, Baas 2020 SITC 2020 poster
For further information, please contact:
Øystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/targovax/r/targovax-s-oncos-102-mesothelioma-24-month-data-shows-class-leading-median-overall-survival,c3364714
https://www.prnewswire.co.uk/news-releases/targovax-s-oncos-102-mesothelioma-24-month-data-shows-class-leading-median-overall-survival-803277007.html